MedWatch

Novo Nordisk: Turoctocog is just the first step

Novo Nordisk admits that the company’s ready-to-launch hemophilia drug, turoctocog alfa, is not markedly different from rival drugs. But the product is merely the first step into the booming hemophilia market. The next step is expected in 2015.

Foto: Novo Nordisk/PR

Turoctocog alfa will be Novo Nordisk’s entrance into the market for hemophilia A, the largest segment of the hemophilia market with an expected total turnover of about 33 billion Danish kroner, just short of 6 billion dollars.

Bu t Novo admits that the launch of the medicine is not exactly a quantum leap for the company.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier